These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 6117379)

  • 1. Lack of beta-adrenoreceptor hypersensitivity after abrupt withdrawal of long-term therapy with oxprenolol.
    Bolli P; Bühler FR; Raeder EA; Amann FW; Meier M; Rogg H; Burckhardt D
    Circulation; 1981 Dec; 64(6):1130-4. PubMed ID: 6117379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Withdrawal of the long-acting beta blocker bopindolol is not associated with beta-adrenoceptor supersensitivity.
    Bolli P; Amann FW; Müller FB; Meyer B; Burckhardt D; Bühler FR
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S64-9. PubMed ID: 2439824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Acute combined alpha- and beta-adrenergic blockade in essential hypertension: effects on blood pressure, renal function, renin, and aldosterone].
    Grüninger U; Akert R; Hunkeler H; Wegmüller E; Weidmann P; Hodler J
    Klin Wochenschr; 1979 Jul; 57(14):731-9. PubMed ID: 470335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta adrenergic blockade and diuretic therapy in benign essential hypertension: A dynamic assessment.
    Davies R; Payne NN; Slater JD
    Am J Cardiol; 1976 Mar; 37(4):637-41. PubMed ID: 3963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adrenergic hypersensitivity after beta-blocker withdrawal in hypertrophic cardiomyopathy.
    Gilligan DM; Chan WL; Stewart R; Oakley CM
    Am J Cardiol; 1991 Sep; 68(8):766-72. PubMed ID: 1892084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. beta-Adrenoceptor hypersensitivity after stopping oxprenolol: discrepant findings not attributable to methodology.
    Singh H; Rimmer A; Lewis MJ; Henderson AH
    Br J Clin Pharmacol; 1983 Dec; 16(6):722-4. PubMed ID: 6318786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Long-term minoxidil therapy: renin, aldosterone, noradrenaline and the need for beta blockers].
    Jaeger P; Brunner HR; Turini GA; Jéquier E; Ferguson RK; Gavras H
    Schweiz Med Wochenschr; 1978 Nov; 108(44):1707-9. PubMed ID: 715407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The renin-angiotensin-aldosterone system and blood pressure during oxprenolol treatment in hypertensive patients pretreated with diuretics.
    Salvetti A; Pedrinelli R; Simonini N
    Int J Clin Pharmacol Ther Toxicol; 1982 Nov; 20(11):538-42. PubMed ID: 6757151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exercise and resting blood pressure and heart rate changes 24 h after dosing in patients with essential hypertension receiving 16/260 oxprenolol Oros once daily.
    Müller FB; Allsopp LF; Cooper GL; Bolli P; Frei P; Glaus L; Ritz R; Bühler FR
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):207S-212S. PubMed ID: 4005124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma noradrenaline concentration in essential hypertension during long-term beta-adrenoceptor blockade with oxprenolol.
    Jones DH; Daniel J; Hamilton CA; Reid JL
    Br J Clin Pharmacol; 1980 Jan; 9(1):27-31. PubMed ID: 7356889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive and hemodynamic effects of oxprenolol versus propranolol.
    Ferlinz J; Easthope JL; Hughes D; Siegel J; Tobis J; Aronow WS
    Clin Pharmacol Ther; 1980 Jun; 27(6):733-43. PubMed ID: 6991196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of propranolol withdrawal phenomena.
    Nattel S; Rangno RE; Van Loon G
    Circulation; 1979 Jun; 59(6):1158-64. PubMed ID: 436208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of oxprenolol on catecholamines and plasma renin activity: acute response to frusemide in hypertensive patients.
    Muiesan G; Alicandri C; Rosei EA; Motolese M; Valori C
    Clin Sci Mol Med Suppl; 1975 Jun; 2():85s-88s. PubMed ID: 802648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of propranolol withdrawal mechanism by prolonged small dose propranolol schedule.
    Rangno RE; Nattel S; Lutterodt A
    Am J Cardiol; 1982 Mar; 49(4):828-33. PubMed ID: 6278914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once daily dosage beta-blockade: antihypertensive efficacy of slow release oxprenolol as related to renin and age.
    Bühler FR; Lütold BE; Küng M; Koller FJ
    Aust N Z J Med; 1976 Aug; 6(3 Suppl):37-43. PubMed ID: 1071402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of two oxprenolol oral osmotic (OROS) delivery systems in patients with essential hypertension.
    McInnes GT; Brodie MJ
    Eur J Clin Pharmacol; 1988; 34(6):605-11. PubMed ID: 3169112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sympathetic reflex responses during treatment of essential hypertension with hydrallazine and oxprenolol.
    Davies IB; Sever PS; Rosenthal T
    Br J Clin Pharmacol; 1979 Jul; 8(1):49-51. PubMed ID: 399592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of indomethacin on plasma renin activity and urinary aldosterone of patients with essential hypertension.
    Pedrinelli R; Arzilli F; Cavasinni L; Poli L; Sassano P; Salvetti A
    J Endocrinol Invest; 1978 Oct; 1(4):315-20. PubMed ID: 756881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxprenolol hydrochloride: pharmacology, pharmacokinetics, adverse effects and clinical efficacy.
    Russo ME; Covinsky JO
    Pharmacotherapy; 1983; 3(2 Pt 1):68-81. PubMed ID: 6344036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haemodynamic consequences of intrinsic sympathomimetic activity in relation to changes in plasma renin activity and noradrenaline during beta-blocker therapy for hypertension.
    Man in't Veld AJ; Schalekamp MA
    Postgrad Med J; 1983; 59 Suppl 3(689):140-58. PubMed ID: 6139800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.